Human Monoclonal Antibody (mAb) Development for Walter Reed Army Institute of Research (WRAIR), Armed Forces Research Institute of Medical Sciences (WRAIR-AFRIMS)

The U.S. Army Medical Research Acquisition Activity (USAMRAA) in support of the Walter Reed Army Institute of Research (WRAIR) Armed Forces Research Institute of Medical Sciences (WRAIR-AFRIMS) intends to negotiate solely (as prescribed in FAR 13.106(b)(1)(i)) with Genovac Antibody Discovery, LLC located at 1810 NDSU Research Circle N, Suite B, Fargo, ND 58102 to perform feasibility studies for the development and production of a panel of fully human mAbs for AFRIMS-supplied target antigens or using AFRIMS-supplied cultured B cells for use in developing immunotherapeutic against bacterial pathogens associated with wound infection and sepsis.

This shall include immunization in transgenic animal model expressing fully human Immunoglobulin G (IgG) antibodies, high-throughput single-cell screening for antigen-specific Antibody-Secreting Cells (ASCs) and cloning and expression of recombinant mAbs for two (2) years. The North American Industry Classification System (NAICS) for this requirement is 541714 and the size standard is 1,000. This announcement constitutes the only notice by the government; a written solicitation will not be issued.

All sources that believe they are eligible to provide these items must respond in writing. Responses must be supported with clear and convincing evidence to clearly articulate the ability to provide the items outlined above. A request for documentation will not be considered an affirmative response. This Special Notice of Intent is not a request for competitive quotes.

Information received will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government. If no written responses are received by the date listed below, the purchase will be awarded without further remark. All questions and responses concerning this notice shall be emailed to Ms. Flodean Billings at flodean.p.billings.civ@health.mil.

Interested concerns must identify their capability in writing to the above e-mail address or by mail to the address listed below no later than 10:00 am ET, 30 April 2024. Contracting Office Address:

US Army Medical Research Acquisition Activity, ATTN: FCMR-ACO-AA, 808 Schreider Street, Frederick, MD 21702-5014.

Point of Contact: Flodean Billings 301-619-2648 flodean.p.billings.civ@health.mil.